JBT-101 in Systemic Lupus Erythematosus (SLE)

Key facts

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Principal Investigator

Meggan Mackay, M.D., M.S.

Northwell Health

Intervention

JBT-101(drug)

Enrollment

109 enrolled

Eligibility

18-70 years · All sexes

Timeline

2017 – 2021

Study locations (16)

• University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La Jolla, California, United States
• UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
• University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center, San Francisco, California, United States
• Yale University, New Haven, Connecticut, United States
• Emory University: Division of Rheumatology, Atlanta, Georgia, United States
• Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, Manhasset, New York, United States
• New York University Langone Medical Center: Department of Medicine, Division of Rheumatology, New York, New York, United States
• Columbia University Medical Center: Department of Medicine, Division of Rheumatology, New York, New York, United States
• Bronx-Lebanon Hospital Center: Division of Rheumatology, The Bronx, New York, United States
• Duke University, Durham, North Carolina, United States
• MetroHealth Medical Center, Cleveland, Ohio, United States
• Penn State MS Hershey Medical Center, Hershey, Pennsylvania, United States
• University of Pennsylvania, Philadelphia, Pennsylvania, United States
• Temple University, Philadelphia, Pennsylvania, United States
• University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh, Pennsylvania, United States
• +1 more locations on ClinicalTrials.gov

Collaborators

Corbus Pharmaceuticals Inc. · Autoimmunity Centers of Excellence · Rho Federal Systems Division, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

• RECRUITINGEARLY PHASE1NCT07107659
  Safety and Efficacy of ONT01 in Lupus
  Hospital for Special Surgery, New York
• RECRUITINGNANCT07558850
  Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGNCT06948110
  Deciphering the Genetic Architecture of Autoimmune Diseases
  National Human Genome Research Institute (NHGRI)
• RECRUITINGPHASE2NCT07409181
  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
  Boehringer Ingelheim
• RECRUITINGPHASE3NCT07332481
  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
  EMD Serono Research & Development Institute, Inc.
• RECRUITINGEARLY PHASE1NCT07526350
  MTS109 in Patients With Refractory Autoimmune Diseases
  Shanghai Changzheng Hospital
• RECRUITINGEARLY PHASE1NCT07490041
  Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases
  The Children's Hospital of Zhejiang University School of Medicine
• RECRUITINGNANCT07470151
  Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

See all trials for Systemic lupus erythematosus →